Heart and Vascular Health
32.5K views | +0 today
Follow
Heart and Vascular Health
Media, News & Topics on prevention, diagnosis & treatment of cardiovascular disease
Your new post is loading...
Your new post is loading...
Scooped by Seth Bilazarian, MD
Scoop.it!

Variability in High-Sensitivity C-Reactive Protein (CRP)

Variability in High-Sensitivity C-Reactive Protein (CRP) | Heart and Vascular Health | Scoop.it

C-reactive protein (CRP) is a marker of systemic inflammation and cardiovascular disease. CRP has been recommended as an adjunct screening tool to stratify cardiovascular risk in the general population. Evidence regarding within-person variability of CRP in the general population is limited. Short-term variability in CRP has important implications for its use & interpretation in clinical practice and research studies.  This study found significant short-term (approximately 2.5 weeks) within-person variability in CRP levels, particularly at high values. Approximately one-third of persons with elevated CRP levels were reclassified as having normal CRP levels after repeated testing. Our results are consistent with those of previous studies conducted in small selected populations (eg, patients with ischemic heart disease) or in which measurements were months or years apart.

more...
No comment yet.
Scooped by Seth Bilazarian, MD
Scoop.it!

Inflammation, Statin Therapy, and hsCRP: Initial Observations

Lecture slides form Dr. Paul Ridker at  ATVB 2011 – Inflammation, Immunity, and Atherosclerosis on Inflammation and Atherothrombosis: Where will new trials take us?

 

Great slide set for review of Inflammation, Statin Therapy, and hsCRP: Initial Observations

 

It discusses the as yet unanswered question can targeted Anti-Inflammatory Therapy Reduce Cardiovascular Risk?

 

Builds the case for why IL-1β inhibition is an attractive target based on experimental data and models and the current understanding of IL-1 and its potential roles in atherogenesis.  Also reviews the candidate therapy, Canakinumab (Ilaris, Novartis) being investigagted in the CANTOS trial.

 

Brief conclusion:

Is there evidence that individuals with elevated levels of inflammatory biomarkers are at high vascular risk even when other risk factors are acceptable? => YES
Is there evidence that individuals identified at increased risk due to inflammation benefit from a therapy they otherwise would not have received? => YES
Is there evidence that reducing inflammation will reduce vascular events? =>

WE NEED TO FIND OUT 

 

For patients with a prior histroy of heart attack (MI) interested in learning more about the CANTOS trial being conducted at PMA, under the direction of Dr. Sunny Srivistava in Haverhill see...

 

http://www.pmaonline.com/clinical-trials.htm

more...
No comment yet.